Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial

BACKGROUND: Asymptomatic left ventricular (LV) dysfunction is highly prevalent in type 2 diabetes patients. Unlike the other hypoglycemic drugs, SGLT2 inhibitors have shown potential benefits for reducing cardiovascular death and risk factors, aside from lowering plasma glucose levels. With this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Natali, Andrea, Nesti, Lorenzo, Fabiani, Iacopo, Calogero, Enrico, Di Bello, Vitantonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639750/
https://www.ncbi.nlm.nih.gov/pubmed/29025406
http://dx.doi.org/10.1186/s12933-017-0615-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639750/
https://www.ncbi.nlm.nih.gov/pubmed/29025406
http://dx.doi.org/10.1186/s12933-017-0615-6

Ejemplares similares